logo

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 11478444 B1

PDFFull Text
Date of Patent:
Oct. 25, 2022

Filed:

Feb. 05, 2021

Use of scientifically matched plant supplements combined with antineoplastic compounds for the treatment of hematological malignancies

Applicant:

Brio Ventures, Llc, Gainesville, FL (US);

Inventors:

Shireen Vali, Irvine, CA (US);

Taher Abbasi, Irvine, CA (US);

Tomas Stopka, Dolní B{hacek over (r)}e{hacek over (z)}any, CZ;

Lubomir Minarik, Prague, CZ;

Neeraj Kumar Singh, Bengaluru, IN;

Shahabuddin Usmani, Bengaluru, IN;

Saumya Radhakrishnan, Sittingbourne, GB;

Huzaifa Sikora, Bengaluru, IN;

Robinson Vidva, Bengaluru, IN;

Kristyna Pimkova, Lednice, CZ;

Assignee:

Brio Ventures, Gainesville, FL (US);

Attorney:

Brio Ventures

Primary Examiner:

Sahar Javanmard

Int. Cl.
CPC ...
A61K 31/26 (2006.01); A61P 35/02 (2006.01); A61K 9/00 (2006.01); A61K 31/05 (2006.01); A61K 31/12 (2006.01); A61K 31/706 (2006.01); A61K 45/06 (2006.01);
U.S. Cl.
CPC ...
A61K 31/26 (2013.01); A61K 9/0053 (2013.01); A61K 31/05 (2013.01); A61K 31/12 (2013.01); A61K 31/706 (2013.01); A61K 45/06 (2013.01); A61P 35/02 (2018.01);
Abstract

The present disclosure relates to the field of combination therapy for treatment of hematological malignancy selected from myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). The disclosure provides a combination therapy comprising plant based compounds and hypomethylating agent (HMA). Particularly, the disclosure provides a combination of: a) a therapeutically effective amount of a combination comprising sulforaphane, resveratrol and curcumin; and b) a therapeutically effective amount of HMA selected from azacitidine (AZA), decitabine (DEC) and a combination thereof, for treating MDS or AML. Said combination provides an enhanced/synergistic effect in the treatment of MDS or AML along with decreasing or overcoming resistance to HMA (azacitidine or decitabine). Methods for decreasing or overcoming resistance to HMA (azacitidine or decitabine), corresponding use of the above described combination and a kit comprising said combination are also provided.

Find Patent Forward Citations

Vali, Shireen. (2022). Use of scientifically matched plant supplements combined with antineoplastic compounds for the treatment of hematological malignancies (U.S. Patent No. 11478444). U.S. Patent and Trademark Office. https://idiyas.com/patent/badge/11478444

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Loading…